… will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic … exclusively on accelerating the development of its Axiomer RNA-editing platform technology. Initial therapeutic areas …
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.
… on developing potential medicines using our Axiomer™ RNA editing platform technology. Strategic collaborations … greater understanding, we can drive higher standards of RNA-editing, medicinal application, and effectiveness of our …
… on developing potential medicines using our Axiomer RNA editing platform technology. Strategic collaborations … exclusively on furthering the development of our Axiomer RNA editing platform technology , which allows selective … in September 2021 , applied ProQR’s proprietary Axiomer™ RNA editing platform to target disorders of the liver and …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
… Agency (EMA) and US Food & Drug Administration (FDA). RNA editing technology – accelerate development of the Axiomer ® RNA base-editing technology platform, including initial focus …
